Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices--United States, December 2021

Authors :: Oliver, Sara E.
Wallace, Megan
See, Isaac
Mbaeyi, Sarah
Godfrey, Monica
Hadler, Stephen C.
Jatlaoui, Tara C.
Twentyman, Evelyn
Hughes, Michelle M.
Rao, Agam K.
Flore, Anthony
Su, John R.
Broder, Karen R.
Shimabukuro, Tom
Lale, Allison
Shay, David K.
Markowitz, Lauri E.
Wharton, Melinda
Bell, Beth P.
Brooks, Oliver
McNally, Veronica
Lee, Grace M.
Talbot, H. Keipp
Daley, Matthew F.
Source :: Morbidity and Mortality Weekly Report. January 21, 2022, Vol. 71 Issue 3, p90, 6 p.
Publication Year :: 2022
Abstract: On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & [...]

Subjects :: United States. Food and Drug Administration
Johnson & Johnson
Vaccination -- Usage
Vaccines -- Usage
Pharmaceutical industry -- Usage
Health

Tools